小鼠CEL-NOS模型中的基因治疗研究
本研究在NOD-scid IL2rγnull小鼠中通过AAV表达IL5构建CEL-NOS模型,4周后单次给予表达抗嗜酸性粒细胞单克隆抗体的AAVrh.10mAnti-Eos(10^11基因组拷贝),结果抗体持续表达>24周,血嗜酸性粒细胞显著降低,死亡率下降。提示单次AAV基因治疗对致死性CEL-NOS具有潜在获益。
要点
- AAVrh.10mAnti-Eos单次给药可长期表达抗嗜酸性粒细胞抗体。
- 治疗组小鼠血嗜酸性粒细胞水平显著低于对照,死亡率降低。
- 该策略为CEL-NOS提供了潜在的一次性基因治疗方向。
核心结论
- 单次AAVrh.10mAnti-Eos治疗可降低CEL-NOS模型小鼠血嗜酸性粒细胞并减少死亡。
研究设计与样本
- 在NOD-scid IL2rγnull小鼠中给予AAVrh.10mIL5构建CEL-NOS模型。
- 给予AAVrh.10mIL5后4周,单次给予AAVrh.10mAnti-Eos(10^11基因组拷贝)。
- 评估抗体表达、血嗜酸性粒细胞计数、器官嗜酸性粒细胞浸润和生存。
主要发现
- AAVrh.10mAnti-Eos持续表达抗嗜酸性粒细胞抗体>24周。
- 治疗组小鼠血嗜酸性粒细胞水平显著低于对照。
- 治疗组小鼠死亡率较对照组显著降低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic eosinophilic leukemia-not otherwise specified (CEL-NOS) is a rare, aggressive, fatal disease characterized by blood eosinophilia and dysfunction of organs infiltrated with eosinophils. Clinically, the disease manifests with weight loss, cough, weakness, diarrhea, and multi-organ dysfunction that is unresponsive to therapy. We developed a one-time gene therapy for CEL-NOS using an adeno-associated virus (AAV) expressing an anti-eosinophil monoclonal antibody (AAVrh.10mAnti-Eos) to provide sustained suppression of eosinophil numbers in blood, thus reducing eosinophil tissue invasion and organ dysfunction. A novel CEL-NOS model was developed in NOD-scid IL2rγnull (NSG) mice by administration of AAV expressing the cytokine IL5 (AAVrh.10mIL5), resulting in marked peripheral and tissue eosinophilia of the heart, lung, liver, and spleen, and eventually death. Mice were administered AAVrh.10mAnti-Eos (1011 genome copies) 4 wk after administration of AAVrh.10mIL5 and evaluated for anti-eosinophil antibody expression, blood eosinophil counts, organ eosinophil invasion, and survival. AAVrh.10mAnti-Eos expressed persistent levels of the anti-eosinophil antibody for >24 wk. Strikingly, CEL-NOS treated mice had markedly lower blood eosinophil levels and reduced mortality when compared with control treated mice. These results suggest that a single treatment with AAVrh.10mAnti-Eos has the potential to provide substantial therapeutic benefit to patients with CEL-NOS, a fatal malignant disorder.
引用
- Pagovich OE, Stiles KM, Camilleri AE, et al. Gene therapy in a murine model of chronic eosinophilic leukemia-not otherwise specified (CEL-NOS). Leukemia. 2021. PMID: 34545183. doi:10.1038/s41375-021-01400-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。